Equities analysts expect China Biologic Products, Inc. (NASDAQ:CBPO) to report earnings of $1.30 per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for China Biologic Products’ earnings. China Biologic Products reported earnings of $1.22 per share in the same quarter last year, which would indicate a positive year over year growth rate of 6.6%. The company is expected to report its next earnings results on Wednesday, November 1st.
According to Zacks, analysts expect that China Biologic Products will report full-year earnings of $5.02 per share for the current financial year. For the next year, analysts forecast that the company will report earnings of $5.86 per share, with EPS estimates ranging from $5.78 to $5.93. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover China Biologic Products.
China Biologic Products (NASDAQ:CBPO) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 EPS for the quarter, topping analysts’ consensus estimates of $1.30 by $0.05. The firm had revenue of $89.28 million during the quarter, compared to analysts’ expectations of $97.33 million. China Biologic Products had a net margin of 31.55% and a return on equity of 21.86%. The business’s revenue for the quarter was down 2.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.26 earnings per share.
Several research analysts have recently commented on CBPO shares. Zacks Investment Research raised China Biologic Products from a “sell” rating to a “hold” rating in a report on Tuesday, July 4th. BidaskClub lowered China Biologic Products from a “hold” rating to a “sell” rating in a report on Sunday, July 16th. Finally, Jefferies Group LLC reissued a “buy” rating on shares of China Biologic Products in a report on Friday, August 4th. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $137.50.
ILLEGAL ACTIVITY WARNING: This article was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/10/18/china-biologic-products-inc-cbpo-expected-to-post-earnings-of-1-30-per-share.html.
Several hedge funds and other institutional investors have recently modified their holdings of the company. First Trust Advisors LP boosted its stake in China Biologic Products by 35.9% in the first quarter. First Trust Advisors LP now owns 11,561 shares of the biopharmaceutical company’s stock worth $1,158,000 after buying an additional 3,053 shares in the last quarter. UBS Asset Management Americas Inc. boosted its stake in China Biologic Products by 9.3% in the first quarter. UBS Asset Management Americas Inc. now owns 198,220 shares of the biopharmaceutical company’s stock worth $19,848,000 after buying an additional 16,933 shares in the last quarter. Geode Capital Management LLC boosted its stake in China Biologic Products by 15.4% in the first quarter. Geode Capital Management LLC now owns 14,309 shares of the biopharmaceutical company’s stock worth $1,432,000 after buying an additional 1,906 shares in the last quarter. Morgan Stanley boosted its stake in China Biologic Products by 157.5% in the first quarter. Morgan Stanley now owns 124,621 shares of the biopharmaceutical company’s stock worth $12,478,000 after buying an additional 76,229 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in China Biologic Products by 70.0% in the first quarter. Renaissance Technologies LLC now owns 249,000 shares of the biopharmaceutical company’s stock worth $24,932,000 after buying an additional 102,504 shares in the last quarter. 72.82% of the stock is owned by institutional investors.
China Biologic Products (CBPO) opened at 81.27 on Wednesday. The stock has a 50 day moving average of $93.15 and a 200-day moving average of $103.13. The company has a market cap of $2.21 billion, a PE ratio of 21.15 and a beta of 1.75. China Biologic Products has a 12-month low of $79.92 and a 12-month high of $125.99.
China Biologic Products Company Profile
Get a free copy of the Zacks research report on China Biologic Products (CBPO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.